Australia markets close in 4 hours 53 minutes

Longeveron Inc. (LGVN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
20.43-5.83 (-22.20%)
At close: 04:00PM EST
19.65 -0.78 (-3.82%)
After hours: 07:18PM EST
Full screen
Trade prices are not sourced from all markets
Previous close26.26
Open23.99
Bid19.30 x 1800
Ask19.56 x 900
Day's range20.15 - 25.66
52-week range2.84 - 45.00
Volume6,426,501
Avg. volume11,058,954
Market cap390.634M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.75
Earnings date14 May 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Longeveron Inc. Announces Pricing of a $20.5 Million Private Placement

    MIAMI, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that it entered into a securities purchase agreement with certain institutional investors to purchase approximately $20.5 million worth of its common stock and warrants in a private placement. Under the terms of the securities purchase agreement, the Comp

  • GlobeNewswire

    Longeveron Announces Phase 2 Clinical Trial in Japan to Test Safety and Efficacy of Lomecel-B on Aging Frailty Patients

    New trial is in collaboration with Japan’s National Center for Geriatrics and Gerontology (NCGG) and Juntendo University HospitalMIAMI, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today that it has entered into a sponsored clinical research agreement with the National Center for Geriatrics and Geron

  • Motley Fool

    Why Longeveron Stock Is Skyrocketing Today

    Shares of Longeveron (NASDAQ: LGVN) were skyrocketing 72.9% as of 11:51 a.m. ET on Wednesday after more than doubling earlier in the day. An epic short squeeze appears to be underway. Longeveron announced on Nov. 18 that the U.S. Food and Drug Administration (FDA) granted a Rare Pediatric Disease designation to experimental drug Lomecel-B in treating a rare congenital heart defect.